ImageneBio, Inc. — Director's Dealing 2025

Jul 30, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ImageneBio, Inc. (IMA)
CIK: 0001835579
Period of Report: 2025-07-25

Reporting Person: Marango Jotin (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-07-28	Common Stock	A	15776	—	Acquired	15776	Direct
2025-07-28	Common Stock	F	4630	$17.16	Disposed	11146	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-07-25	Stock Option (Right to Buy)	$	D	181000	Disposed		Common Stock (181000)	Direct
2025-07-25	Stock Option (Right to Buy)	$	D	105000	Disposed		Common Stock (105000)	Direct
2025-07-25	Stock Option (Right to Buy)	$	D	397199	Disposed		Common Stock (397199)	Direct

Footnotes

F1: In connection of the closing of the Merger between the Company (formerly known as Ikena Oncology, Inc. ("Ikena")) and Inmagene Biopharmaceuticals, shares of the combined company were issued on July 28 in exchange for certain options held by the holder in Ikena.